Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.995,07 +366,59 (+0,97%) EUR/USD
1,0732 -0,0001 (-0,01%) Bitcoin EUR
60.135,01 +263,13 (+0,44%) CMC Crypto 200
1.391,55 -4,98 (-0,36%)
Tarsus Pharmaceuticals, Inc. (TARS)
Dopo ore:
| Chiusura precedente | 32,76 |
| Aperto | 31,85 |
| Denaro | 32,12 x 200 |
| Lettera | 32,24 x 100 |
| Min-Max giorno | 31,49 - 32,62 |
| Intervallo di 52 settimane | 12,57 - 40,40 |
| Volume | |
| Media Volume | 729.514 |
| Capitalizzazione | 1,208B |
| Beta (5 anni mensile) | 1,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,62 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 53,38 |
GlobeNewswireTarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman, will ring the closing bell at the Nasdaq Stock Market on Wednesday, September 6, 2023. The event marks the launch of XDEMVY™, which is now available at pharmacies nationwi
- GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY: H.C. Wainwright 25th Annual Glo
- GlobeNewswire
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and optometrists nationwide IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology
